Liminatus Pharma Inc. (NASDAQ:LIMN) Short Interest Update

Liminatus Pharma Inc. (NASDAQ:LIMN) was the target of a significant increase in short interest in the month of May. As of May 29th, there was short interest totaling 1,228,229 shares, an increase of 118.4% from the May 14th total of 562,363 shares. Based on an average daily volume of 44,575,019 shares, the short-interest ratio is presently 0.0 days. Approximately 2.7% of the company’s shares are sold short.

Liminatus Pharma Stock Performance

LIMN stock traded down $0.01 during midday trading on Friday, hitting $0.12. 2,221,562 shares of the company’s stock were exchanged, compared to its average volume of 22,322,348. The stock’s fifty day moving average price is $0.18 and its 200-day moving average price is $0.46. Liminatus Pharma has a one year low of $0.12 and a one year high of $33.66.

Liminatus Pharma (NASDAQ:LIMN) last posted its earnings results on Friday, May 15th. The company reported ($0.03) earnings per share for the quarter.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Liminatus Pharma in a research note on Friday, March 27th. One analyst has rated the stock with a Sell rating, According to MarketBeat.com, the stock currently has an average rating of “Sell”.

About Liminatus Pharma

Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.